New research from Emory University evaluated immune responses after the 2023–24 COVID vaccine. The study, published in Science and Translational Medicine, followed 24 participants for six months and measured memory B cells, binding antibodies, and neutralizing antibodies. The 2023–24 vaccine was monovalent and designed to match the then-dominant Omicron XBB.1.5 variant; previous vaccines had been bivalent.
Laboratory tests showed the vaccine produced antibodies with a half-life of more than 500 days, so at least half remained detectable more than 16 months after vaccination. Participants also produced cross-reactive antibodies that recognized both the ancestral WA1 strain and XBB.1.5. The researchers said immune imprinting likely contributed to a 2.8-fold increase in these cross-reactive antibodies.
The paper notes that SARS-CoV-2 has caused more than 1.2 million deaths nationwide and has many mutations. It also lists groups at higher risk of severe disease, such as people with cancer, autoimmune disorders, stroke, obesity, and existing heart, kidney, lung, or liver conditions.
Difficult words
- memory B cells — White blood cell that remembers past infections
- binding antibodies — Protein that binds to a virus or germ
- neutralizing antibodies — Antibody that can stop a virus infecting cells
- monovalent — Designed to target one strain or variant
- bivalent — Designed to target two different strains together
- half-life — Time for half of a substance to disappear
- immune imprinting — When first immune exposure shapes later responses
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Which of the risk groups named in the article would you put first for vaccine access in your community, and why?
- If antibodies remain detectable for many months, how might that change people’s plans for booster shots?
- How would you feel about a vaccine made to match a single dominant variant versus one that targets two variants? Explain briefly.
Related articles
PAHO issues first guide for tungiasis treatment
PAHO has published the first evidence-based guide to treat tungiasis, recommending low-viscosity dimethicone and warning against unsafe manual removal. The disease affects millions in Latin America, the Caribbean and Sub-Saharan Africa.
Convenient healthy meals and depression
A University of Michigan study tested whether making healthy meals more convenient could reduce depressive symptoms. Both self-prepared and delivered minimally processed meal plans improved diet quality, and the delivery group showed larger mood improvements.
Billions face cooling poverty as heat rises
A global study finds billions of people live in "cooling poverty" as hot spells become more frequent and intense. Researchers call for low-cost, coordinated policies across housing, water, health and cities because air conditioning alone is not enough.